Efficacy and Safety of Intranasal Esketamine in Patients With Treatment-Resistant Depression and Comorbid Chronic Post-traumatic Stress Disorder : Open-Label Single-Arm Pilot Study Maud Rothärmel, Cherifa Benosman, Wissam El-Hage, Caroline Berjamin, Diane Ribayrol, Olivier Guillin, Raphaël Gaillard, Lucie Berkovitch and Virginie Moulier Frontiers in Psychiatry, 2022 | Volume 13 | Article 865466 doi : 10.3389/fpsyt.2022.865466 Abstract Introduction: Major depressive disorder (MDD) is more likely to resist to usual treatment when it is associated with post-traumatic stress disorder (PTSD). Capitalizing on the effect of ketamine in both treatment-resistant depression (TRD) and PTSD, we conducted a study in order to assess the efficacy of intranasal (IN) Esketamine in [...]
Lire la suiteTowards mapping neuro-behavioral heterogeneity of psychedelic neurobiology in humans Flora Moujaes, Katrin H. Preller, Jie Lisa Ji, John D. Murray, Lucie Berkovitch, Franz X. Vollenweider, Alan Anticevic Biological Psychiatry, 2023 doi : 10.1016/j.biopsych.2022.10.021 ABSTRACT Precision psychiatry aims to identify markers of inter-individual variability that allow predicting the right treatment for each patient. However, bridging the gap between molecular-level manipulations and neural systems-level functional alterations remains an unsolved problem in psychiatry. After decades of low success rates in pharmaceutical R&D for psychiatric drugs, multiple studies now point to the potential of psychedelics as a promising fast-acting and long-lasting treatment for some psychiatric symptoms. Yet, given the highly [...]
Lire la suiteBibliographie : "Substances psychédéliques et prise en charge des PTSD", Dr Christian Sueur, GRECC, mars 2023
Lire la suiteBibliographie MDMA - PTSD Dr Christian Sueur, mars 2023
Lire la suiteThe Efficacy of MDMA (3,4- Methylenedioxymethamphetamine) for Post- traumatic Stress Disorder in Humans : A Systematic Review and Meta-Analysis Sarah Tedesco , Ganeya Gajaram , Shahzad Chida , Arham Ahmad , Meghan Pentak , Marina Kelada , Layth Lewis , Deepa Krishnan , Carolyn Tran , Oladipo T. Soetan , Lawrance T. Mukona , Ayodeji Jolayemi Cureus, 13, (5), e15070. Doi : 10.7759/cureus.15070 Abstract Background : 3,4-methylenedioxymethamphetamine (MDMA), known recreationally as “Molly” or “Ecstasy”, is a triple monoamine reuptake inhibitor. MDMA specifically acts as a weak 5-HT1 and 5-HT2 receptor agonist, targeting 5-HT2A, 5-HT2B, and 5-HT2C receptors. Its potential use for therapeutic purposes with these pharmacological [...]
Lire la suiteBibliographie MDMA - Ecstasy Docteur Christian Sueur, GRECC, mars 2023 MDMA : généralités, sociologie…, pp 1 - 3. MDMA : pharmacologie, pp 4 - 9. MDMA : neurophysiologie, pp 10 - 15. MDMA : toxicologie, pp 16 - 22. MDMA : analyses pharmacologiques, « réduction des risques », pp 23 - 24. MDMA : psychopathologie, pp 25 - 26. MDMA : enthéogénie, p 27. MDMA : thérapeutique, pp 28 - 34.
Lire la suiteCannabis and mental illness : a review Darby J. E. Lowe · Julia D. Sasiadek · Alexandria S. Coles · Tony P. George European Archives of Psychiatry and Clinical Neuroscience, 2018, 1-14. Doi : 10.1007/s00406-018-0970-7 Abstract With the increasing push to legalize cannabis in Western nations, there is a need to gage the potential impact of this policy change on vulnerable populations, such as those with mental illness, including schizophrenia, mood, and anxiety disorders. This is particularly important as there are strong motives in these individuals to seek short-term reward (e.g., “getting high”). Nonetheless, data to support the beneficial effects of cannabis use in psychiatric [...]
Lire la suiteAssessment of Orally Administered Δ9-Tetrahydrocannabinol When Coadministered With Cannabidiol on Δ9-Tetrahydrocannabinol. Pharmacokinetics and Pharmacodynamics in Healthy Adults : A Randomized Clinical Trial C. Austin Zamarripa, PhD; Tory R. Spindle, PhD; Renuka Surujunarain; Elise M. Weerts, PhD; Sumit Bansal, PhD; Jashvant D. Unadkat, PhD; Mary F. Paine, PhD; Ryan Vandrey, PhD Jama Network Open, 2023, 6, (2), e2254752, 1-15. doi : 10.1001/jamanetworkopen.2022.54752 Key Points Question : Are there acute pharmacokinetic or pharmacodynamic differences between oral ingestion of a Δ9-tetrahydrocannabinol (Δ9-THC)- dominant cannabis extract compared with a cannabidiol (CBD)-dominant extract at the same Δ9-THC dose (20 mg) in healthy adults who use cannabis infrequently? Findings : In this randomized clinical trial including 18 [...]
Lire la suiteMort de Raphael Mechoulam, le « père de la recherche sur le cannabis » en Israël Le scientifique a mené des recherches pionnières sur le cannabis, dont les résultats ont permis à cette substance de passer de la contre-culture au courant dominant Par ANDREW SILOW-CARROLL Times of Israël, 12 mars 2023, 16:20 Le professeur Raphael Mechoulam dans son laboratoire du campus Ein Kerem de l’Université hébraïque, le 1er septembre 2016. (Crédit : Melanie Lidman/Times of Israel) JTA — Au début des années 1960, un scientifique d’origine bulgare nommé Raphael Mechoulam est surpris avec cinq kilogrammes de ce qu’il qualifie « de magnifique haschisch libanais de contrebande » [...]
Lire la suiteNegative experiences of patients using medicinal cannabis : A systematic review of qualitative studies Or Gliksberg, P Talma Kushnir, Sharon R. Sznitman, Shaul Lev-Ran, Silviu Brill, Ben H. Amit, Daniel Feingold PhD, Journal of Clinical Nursing, 2023, 1-12. doi : 10.1111/jocn.16653 Abstract Aims and Objectives : In this study, we systematically reviewed qualitative studies concerning patients' experience with medicinal cannabis (MC) use, to gain insight into the negative effects of MC. Background : Over the past decades, the use of MC for therapeutic purposes has increased. However, there is conflicting and insufficient data on possible negative physiological and psychological effects of MC treatment. Design : A systematic review was [...]
Lire la suite